Review the old and learn the new, nostalgia and gratitude丨Let us continue to move forward and create great achievements

Twenty-one years of growth

shengnuo biotechnology was established in 2001, and its main business is the research and development, production and sales of peptides and peptide-related products. He has won many honors such as National High-tech Enterprise, Sichuan Polypeptide Drug Engineering Technology Research Center, and Sichuan Province Major Scientific and Technological Achievement Transformation Project Demonstration.

Initially, our core business mainly consisted of peptide APIs and preparations, and related pharmaceutical products mainly covered the fields of chronic hepatitis B, reproduction, and HIV.

In addition, SinoBio has been providing CDMO services for innovative peptide drug companies since its establishment. On this basis, we have gradually established a production platform for the entire industry chain of peptide APIs and peptide preparations, which is also one of the first few in China. One of the teams with CDMO mode.

Now, in the first year of SinoBio’s listing, we have entered a new track – new crown specific drugs and peptide medical beauty.

In the future, shengnuo biotechnologylogical will enter a state of blooming with new growth industries based on peptide APIs and preparations, CDMO, new crown specific drug research and development, and peptide medical beauty.

Steady business growth

In the 2021 annual report data of shengnuo biotechnology, we have made announcements:

In 2021, the company will achieve an operating income of 387 million yuan, a year-on-year increase of 2.05%, and a net profit of 61.2528 million yuan, a year-on-year increase of 2.09%.

In the first quarter of 2022, the company achieved operating income of 80.7448 million yuan, a year-on-year decrease of 13.44%, net profit of 14.2929 million yuan, a year-on-year increase of 22.64%, and basic earnings per share of 0.18 yuan.

On May 25, 2022, we announced that we will distribute dividends of 3 yuan per 10 shares in 2021.

In the 2021 annual financial report, shengnuo biotechnology has achieved stable growth in revenue and profits, and at the same time actively distributed equity dividends. In the first quarter of 2022, although the revenue of shengnuo biotechnologylogical declined slightly, the profit side maintained steady growth and the profit margin was good.

Multi-line research and development, enhance the competitiveness of enterprises

With the advent of the post-epidemic era, the domestic anti-epidemic has gradually put forward higher requirements, and shengnuo biotechnology has begun to think about changes. In addition to independent research and development, shengnuo biotechnology has also set its sights on peptide new crown special drugs, through the acquisition of patented technology , entered the field of new crown specific drug research and development.

Event review: In 2022, shengnuo biotechnology announced its entry into the new crown track with the transfer of the patent of Aoda Bio’s anti-new crown virus polypeptide drug. According to relevant information, this patent will be used to develop a nasal spray-type peptide specific drug for the new crown. The project strives to apply for China’s clinical approval before the end of 2022. It is estimated that it will take 2-3 years to complete the project, and the total investment is expected to be RMB 1.75 billion.

In addition, shengnuo biotechnologylogical has also made a layout for the research and development of polypeptide medical beauty.

Event review: On November 8, 2021, the company’s president office meeting reviewed and approved the foreign investment capital increase proposal. The company subscribed for 13.0434% of the equity of Chengdu Gechun Biopharmaceutical Co., Ltd. through its wholly-owned subsidiary Shengrong Langke for RMB 15 million. And on March 2, 2022, Shengrong Netac, a wholly-owned subsidiary, acquired a 49% stake in Guangzhou Shengjing Shangmei Biotechnology Co., Ltd. for RMB 24.5 million. In the future, the main business of these two companies will focus on medical beauty competition. road.

For shengnuo biotechnology, this is an expansion of the track and a supplement to the research and development level.

On June 6, shengnuo biotechnologylogical ushered in the lifting of the ban on some shares. Along the way, shengnuo biotechnology has been favored by many investors and has also received a lot of media attention. The growth of the company is inseparable from the joint efforts of all employees, and even more inseparable from the support of investors and partners.

The vicissitudes of life, the long years.

The short one-year listing period is like a flashback. For shengnuo biotechnology, the recognition of investors and the support of partners is a great honor for shengnuo biotechnology.

We also firmly believe in the industrial value and track potential of shengnuo biotechnology, and we sincerely welcome investors to continue to work with us to write a new chapter in the future of shengnuo biotechnology.